# NSCLC FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/nsclc

> 4 upcoming FDA catalysts in NSCLC: EIK1001 (EIKN) on December 2026 (primary completion); EIK1001 (EIKN) on Dec 2026 to Mar 2027 (topline data readout); Imfinzi® (durvalumab, AZN) on November 2027 (primary completion); Imfinzi® (durvalumab, AZN) on Nov 2027 to Feb 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 2026 | [EIK1001 primary completion](https://sec-api.dev/pdufa/eik1001) | EIKN | NSCLC | scheduled | "NCT06246110 (A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Eikon Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06246110)) |
| Dec 2026 to Mar 2027 | [EIK1001 topline data readout](https://sec-api.dev/pdufa/eik1001) | EIKN | NSCLC | scheduled | "NCT06246110 (A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Eikon Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06246110)) |
| November 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | NSCLC | scheduled | "NCT05687266 (Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05687266)) |
| Nov 2027 to Feb 2028 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | NSCLC | scheduled | "NCT05687266 (Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05687266)) |

## Drugs

- [EIK1001](https://sec-api.dev/pdufa/eik1001) (EIKN)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/nsclc.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NSCLC FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/nsclc

```bibtex
@misc{secapidev_indications_nsclc_20261116,
  title        = {NSCLC FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/nsclc}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_nsclc_20261116","title":"NSCLC FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/nsclc","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
